Important Facts About Trodelvy:
Drug Name: Trodelvy (Sacituzumab govitecan-hziy)
FDA Approval: Yes (First approved April 22, 2020)
Indication: This therapeutic drug is approved for the treatment of metastatic triple-negative breast cancer (mTNBC), HR-positive/HER2-negative breast cancer, and bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery.
Mechanism of Action: Trodelvy is an antibody-drug conjugate (ADC) that targets Trop-2, a protein found on the surface of many types of cancer cells. It delivers a chemotherapy agent, SN-38, directly to cancer cells, helping to kill them while minimizing damage to healthy cells.
Efficacy: Clinical trials have demonstrated significant improvement in progression-free survival (PFS) and overall survival in patients with mTNBC, HR-positive/HER2-negative breast cancer, and cancers of the urinary tract.
Administration: The recommended dosage of Trodelvy injection is administered intravenously (IV).
Side Effects: Common side effects include fatigue, vomiting, nausea, diarrhea, hair loss, decreased appetite, and anemia. Serious side effects may include neutropenia, febrile neutropenia, and diarrhea.
Monitoring: Patients receiving Trodelvy may require monitoring of blood counts and liver function tests.
Cost: Trodelvy can be expensive. To inquire about the exact cost of Trodelvy injection, you can contact Indian Pharma Network (IPN) directly. We can provide up-to-date pricing information and assist you with any questions you may have regarding the medicine.
Important Safety Information of Trodelvy:
Trodelvy (sacituzumab govitecan-hziy) is an important medication used to treat certain types of cancer. However, it’s important to be aware of its safety information:
Infusion Reactions: Trodelvy can cause infusion reactions, which may include chills, fever, flushing, shortness of breath, or wheezing. These reactions typically occur during or within 24 hours of the infusion. Inform your healthcare provider (HCP) promptly in case you experience any of these signs and symptoms.
Severe Neutropenia: Trodelvy can lead to a significant decrease in white blood cell (WBC) count, increasing the probability of infections. Your clinician will monitor your blood cell counts regularly throughout treatment.
Diarrhea: Diarrhea is a common side effect of Trodelvy injection and can be severe. Your clinician may prescribe medicines to manage diarrhea effectively.
Interstitial Lung Disease (ILD): ILD, which can be fatal, has been reported with Trodelvy treatment. Inform your doctor immediately if you experience any new or worsening respiratory symptoms, such as cough, difficulty breathing, or fever.
Hematologic Toxicity: Trodelvy may cause critical or fatal hematologic toxicity, including thrombocytopenia and anemia. Your healthcare provider (HCP) will monitor your blood counts on a regular basis.
Embryo-Fetal Toxicity: Trodelvy can be responsible for causing harm to unborn babies. Consider effective contraception throughout treatment and for a certain period afterward.
It’s necessary to discuss any concerns or potential side effects with your healthcare provider (HCP) prior to starting treatment with Trodelvy. They can provide personalized guidance and monitor your health throughout the treatment process. Always follow their instructions carefully to ensure safe and effective use of the medicine.
Reference:
https://www.trodelvy.com/
